TiGenix to Raise Capital via a Private Placement of New Ordinary Shares

19 December 2012 - Leuven, Belgium – TiGenix NV (Euronext Brussels: TIG) today announced that it will launch a private placement of up to 8,629,385 new ordinary shares.


TiGenix will use the funds mainly for the commercial roll out of ChondroCelect in selected European markets and for progressing with the clinical development of Cx601 in complex perianal fistulas in Crohn's patients.

The new shares will be placed through an accelerated bookbuilding procedure. The placing will start on 19 December 2012. The Company has asked the Financial Services and Markets Authority (FSMA) to suspend its shares from trading on NYSE Euronext Brussels. Trading in the share will resume shortly following the publication of the results of the placing.

The Company will announce the results of the placing as soon as possible after closing of the bookbuilding.

Source : tigenix.com

Une app smartphone mesure votre état de santé en temps réel

17 Décembre 2012 - Une apps smartphone révolutionne le monde médical.

Une révélation pour tous les hypocondriaques ou autres soucieux de leur santé qui grâce à cette nouvelle application pourront contrôler à la fois leur fréquence cardiaque, poids, pression artérielle, ou encore de surveiller taux de cholestérol et de glycémie.

Examiner sa santé au quotidien ne sera plus l'affaire des généralistes ou des médecins spécialisés, mais l'opportunité de tout un chacun. Cette application a été accueillie comme la médecine préventive du futur.

Source : siliconwadi.fr
http://siliconwadi.fr/5890/une-application-smartphone-mesure-votre-etat-de-sante-en-temps-reelle

TiGenix Reacts to Rumors

Leuven, Belgium – 14 December 2012 

TiGenix NV (Euronext Brussels: TIG) announces that, apparently as a result of unauthorized access to certain non-public sections of TiGenix’s website, draft announcements regarding a potential capital increase by way of a private placement have surfaced today on certain internet forums.

As is common in the biotech sector, the company regularly examines and prepares for opportunities to secure additional financing, including the possibility of a capital increase.

However, TiGenix has not taken a decision to engage in such a transaction at this point in time. If and when such a transaction were to be decided, the company will inform the market in due course.
More info : Tigenix.com